Celldex Therapeutics (CLDX) Equity Average (2016 - 2025)
Celldex Therapeutics (CLDX) has 15 years of Equity Average data on record, last reported at $562.8 million in Q4 2025.
- For Q4 2025, Equity Average fell 26.58% year-over-year to $562.8 million; the TTM value through Dec 2025 reached $562.8 million, down 26.58%, while the annual FY2025 figure was $637.1 million, 8.33% up from the prior year.
- Equity Average reached $562.8 million in Q4 2025 per CLDX's latest filing, down from $626.9 million in the prior quarter.
- Across five years, Equity Average topped out at $826.1 million in Q2 2024 and bottomed at $188.2 million in Q2 2021.
- Average Equity Average over 5 years is $471.7 million, with a median of $395.2 million recorded in 2022.
- Peak YoY movement for Equity Average: surged 205.11% in 2024, then fell 26.58% in 2025.
- A 5-year view of Equity Average shows it stood at $428.1 million in 2021, then decreased by 21.56% to $335.8 million in 2022, then rose by 0.64% to $337.9 million in 2023, then soared by 126.8% to $766.5 million in 2024, then fell by 26.58% to $562.8 million in 2025.
- Per Business Quant database, its latest 3 readings for Equity Average were $562.8 million in Q4 2025, $626.9 million in Q3 2025, and $679.2 million in Q2 2025.